Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
: f# i" {- O6 {5 m; I1 s- a; n$ m
% R; }7 x7 R+ c" h
. c s- O! s( F. f9 N$ h' bSub-category:3 J6 R; e. m1 `8 _' [' d; v! X* v( u- X
Molecular Targets - x* Z; n/ u$ y+ T# B
- h& S& `, l! j4 |# Z7 S* K+ o# O8 G% l' O/ Q, z7 P
Category:/ V9 l- F" _7 Z( ]0 m0 E, J. O$ F6 ^$ S: X
Tumor Biology + k4 h- j6 j* V6 g
3 k( {: P! h/ X5 N2 x% B3 `+ \! Z% A6 U
Meeting:
: U* M. e4 U+ h' L9 _2011 ASCO Annual Meeting # |* F* X+ ?) m
/ ^/ w `- V7 n/ g2 c* D' [( s' o( n: |2 [. ~, k) s+ N
Session Type and Session Title:
3 D# q" y$ ]. v7 }; r$ f, nPoster Discussion Session, Tumor Biology
& f% Y" K1 ]- Q6 ?' O1 K) P8 W" Y- C' B/ L$ y% G: I9 \4 o
9 q: U5 D6 C% \7 g8 g( n% WAbstract No:
3 M A; n2 j& W) E& Y10517
0 w' k+ Q- D7 Q, a' S+ X7 p! {1 `5 p4 Z1 E) m. c4 }
% i1 t9 K& _' k' E% gCitation:0 V# f3 k3 Z* ?: ~ d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
# P: J! _8 j" G" S2 ^' g. P: D( V) T3 F' [+ g9 P) ~* X' L
( J3 F) s+ ?* w' |; R2 c0 W
Author(s):- u: O' P8 z% f) ]( d* f
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " |/ b$ C# L, I- ?
' \; T' z( q1 @! d$ f) Q
7 t* [* j3 E) J; v4 Y) C# g; X5 E* B% |, d0 G% b. X
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& E' ^' g% P/ H5 V z
$ A% ]. A8 k& zAbstract Disclosures4 Z" V! R; f, h+ m( P
$ ?$ x6 X- u0 B7 c, f
Abstract:0 a; C+ J2 u" a2 s2 n
8 p5 x7 S d! x4 O: C& |+ m- O7 u! ^- { E
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
+ V. D2 k7 T' d& @+ b8 L0 b( l. s% Z0 q3 M( l; [, Y
& D* n( y6 s6 u/ u- C. q |